Home / Transcripts / Demant A/S (DEMANT) · August 15, 2024

Demant A/S (DEMANT) Earnings Call Transcript

August 15, 2024

Nasdaq Copenhagen DK Health Care Health Care Equipment and Supplies earnings 60 min

Earnings Call Speaker Segments

Peter Pudselykke executive
#1

We're going to walk through a presentation that covers both of the topics, and as always, once we're finished we'll move into Q&A. A quick practical note: the presentation ought to be available on our website now, and as usual, we're planning for this call to run no longer than one hour, Q&A session included. Joining us on the call today, as always, are Søren Nielsen, our President and CEO, René Schneider, our CFO, and from the IR team, Gustav Høegh along with myself, Peter Pudselykke. With that brief introduction, I'll hand things over to Søren — please go ahead.

Søren Nielsen executive
#2

Thank you so much, Peter. Today's agenda covers key events, takeaways on the financial side, sustainability accomplishments, and a somewhat deeper dive into the business areas to add more color and flavor regarding how things are progressing. René will walk through the group financials and talk a bit more about the EPOS restructuring, and then I'll wrap up with the outlook, and after that we can move to Q&A. One key event for first half performance in the first half was, obviously, and as was announced earlier in July, below expectations. After our revised view on the second half as well, we reduced the group's expectations for growth and EBIT. A major or key factor in that is the development, the current development, in the hearing aid business. Beyond that, we also saw the diagnostic business grow at a slower pace than anticipated. U.S. hearing aids being affected by, and more negatively affected, as we've discussed, by the brand strategy we chose in the U.S. I'll go into that more in the business area. In hearing care, good, strong momentum, accelerating as expected from Q1 into Q2, and delivered strong performance, and has further been supported by continued acquisition. As announced on May 21st, we have closed the divestment of our cochlear implant business to cochlear.

Søren Nielsen executive
#3

The bone-anchored hearing aid system business is still part of the group at this point, and a review of strategic options for it is also pending. That business is performing well, delivering profit and solid results. We have wrapped up the strategic review on communications, and on that basis we decided to kick off a strategic — or a significant — restructuring process aimed at resizing the organization so it aligns better with current revenue, and after that, to keep seeking a new owner and divest the business. A bit more on EPOS. We have now finished the process we initiated, and there are a few key takeaways from that strategic review. First, it remains Demant's strategy to become a focused hearing healthcare company, which means we will keep pursuing the effort to divest the business. Second, the process did confirm that the company holds good value. It has strong technology. It has good market exposure and a robust go-to-market model. However, it is clear that certain investments made over the past year have not delivered the expected return and have not been able to grow the top line sufficiently. So financial results ultimately became the obstacle to reaching an agreement with a potential buyer, and as a result we have decided, as of today, to initiate a significant restructuring plan, so that the business will be resized to an organization that fits the top line, but focused precisely on the things that deliver return, where we know we drive the top line, and where there is a good correlation between money spent and money made, going forward.

Søren Nielsen executive
#4

And several of the initiatives we've put money into — you know, the ones with a long-term angle and a growth plan — haven't been able to deliver, so those will be pulled back and given lower priority. That way we can end up with a smaller organization capable of concentrating on executing against its core strengths. The work of locating a new buyer or new owner and divesting that business will be started up again as soon as we've demonstrated that we can produce results — positive results — and have shown, which I'm confident we can, a stable business, a more stable business, that turns in good results day in and day out. René will go deeper into the financial side of this in his section. So the key financial takeaways from the first half: organic growth for the group came in at 3%, which is under expectations. We regard ourselves as a company that, continuously, gains market share and grows faster than the market. That clearly isn't the situation in the first half year, and so it's below what we expected. The bright spot in it — though it's a consequence of especially the customer mix — is that we've witnessed a very strong move in the gross margin, driven by a fairly significant, or a nice, lift in ASP, but mainly because a number of lower-priced units sold to customers who typically purchase in bigger volume at lower prices haven't bought in line with expectations, and also because of some improvements in the diagnostic business.

Søren Nielsen executive
#5

Operating expenses rose 7% organically during the first half, and part of that reflects the buildup we had last year — as we mentioned previously, we entered the year very cautiously, but once the strong results started coming through, we chose to put more money into the company's future, which is why we saw that ramp-up over the course of the year. EBIT before special items came in at DKK 2.068 billion, down 4%, which is, of course, again not satisfactory and below what we expected, and so the margin fell 1.5 percentage points because of lower operating leverage. The business generated very strong cash flow, with cash flow from operations of roughly DKK 1.5 billion and free cash flow of DKK 1.157 billion Danish kroner. Our updated guidance is now 2%-4% organic growth for the group and EBIT before special items of DKK 4.3 billion-DKK 4.6 billion, as we announced in July. On sustainability progress in the first half, we recorded a 3% rise in our Scope 1 and 2 CO2e emissions. That is entirely tied to further expansion in hearing care. We must, of course, also commit to cutting the emissions that come from these acquisitions and, more broadly, to further strengthening our efforts — or lowering our emissions.

Søren Nielsen executive
#6

We have, however, managed to raise the proportion of renewable energy during this period, and in the next six to 18 months we genuinely anticipate a substantial improvement there. Women now make up 30% of top management, which had been our 2025 target, so we are reaching it early. Business area review. To begin with the hearing aid market — I'm sure lots of you watch it closely — the broad picture is that this market is still solid and strong, posting 5% unit growth in Q2 after 3% in Q1. The mix, though, was a bit different, with more growth in Europe, chiefly from the NHS in the U.K., the government channel expanding through a mix of a fairly large rise in privately fitted public instruments plus hospitals with rising volume. Meanwhile, the commercial side of the U.S. business fell versus Q1 and settled at a more normal level of 6%. VA and the U.S. continue to trail expectations, growing just 1%, which still reflects rehiring constraints as staff depart amid broader budget limits. For the rest of the world, we continue to project comparatively modest positive growth, and one of the biggest drags is China, where market development still looks somewhat difficult.

Søren Nielsen executive
#7

On the hearing aids side in Q2, organic growth to external customers came in at just 1%. A major market-share loss in U.S. managed care is definitely the largest factor in that picture, but we've also shed some volume across quite a few channels and customer segments where pricing is the main focus. As a result, we're looking at a half year with unit development down 6%, yet thanks to product mix, customer mix, channel mix and geography mix, ASP development was a strong +11%. That, in turn, is what underpins a solid gross margin for the business. Europe is delivering across many medium-sized markets, with France slightly negative on account of market development. The U.K. is growing below market, again because we currently don't play in what we call AQP, the privately fitted government instruments. We've then seen strong growth in VA, with nice uptake versus last year and continued share expansion. Canada posted very strong growth, while the U.S. was negative, driven by the significant managed-care share loss, which in the short run we haven't been able to offset through extra sales to independent dispensers.

Søren Nielsen executive
#8

That isn’t to say it isn’t occurring, but it hasn’t occurred at a pace that lets us offset the more negative response than expected from some participants in the managed care segment. China showed slight positive growth despite rather unfavorable market conditions, so clearly we gained share, and there was solid growth across several other medium-sized Asia Pacific markets. As I mentioned, hearing care in the second quarter had the anticipated pickup in momentum from Q1 into Q2. We observed that late in Q1, along with some favorable momentum in France, robust growth in numerous mid-sized European countries, and then a good contribution from acquisitions, especially in Germany and Belgium, consistent with our strategy. Canada delivered a strong performance, and there we also saw positive growth in light of a substantial shift in mix between private pay customers and managed care customers; I’m very pleased that we have succeeded in changing the mix at our own stores, which sets things up well for the future. Australia grew positively, while China declined because of market headwinds. Diagnostics was flat in the second quarter, 0% growth, which I would call unusual.

Søren Nielsen executive
#9

As you're aware, this business has been able to produce solid organic growth for a lot of years. We're so large in this market that this says more about, you'd say, how the overall market is developing than about any share loss — and we see no sign of that happening. Quite the opposite: it's particularly access to the Chinese markets that has grown harder and harder unless production is done in China. And we currently have two smaller portfolios of products manufactured in China for the Chinese market. Naturally, we're working to change that, though it can't be done overnight — but we are on it. And then there's negative growth in our balance products. Those two things, taken separately, are what truly drive the flat sales. The remainder of the business has performed as we expected. Positive growth contribution from service, consumables, all the other categories, and in particular the hearing instrument fitting, where we continue to see a nice development. Over to you, René.

René Schneider executive
#10

Thanks. As we walk through the financial review of the figures, beginning with revenue, we reported 4% growth. Within that, 3% came from organic growth, and that is under our expectations, pushed by hearing aids and diagnostics, even taking into account the tough comparables from last year. Organic growth came in at 3% in both Q1 and Q2. Acquisitions added 2%, mostly from hearing care, plus a modest positive contribution from hearing aids in the second quarter, and finally, FX was -1%. Turning to gross profit for the first half year, it showed very solid growth of 6% along with a fairly substantial margin gain of 1.8 percentage point, which beats expectations and has come from favorable ASP development and a really strong product mix in hearing aids, as well as a meaningful improvement in gross margin within diagnostics. Those are the two main drivers, and on top of that, a slight positive effect from both business mix and FX. Operating expenses for the first half year rose 7% organically and 3% from the acquisitions mentioned earlier. Looking at the organic growth in operating expenses, you may remember that we posted low double-digit growth in the first quarter, which essentially means second quarter organic OpEx growth was mid-single digit.

René Schneider executive
#11

You've observed a slowdown in our OpEx growth from Q1 to Q2, and we anticipate that slowdown will carry on through the second half of the year, partly because we annualize last year's step-up in OpEx, and partly because of the initiatives we've launched after our top line growth came in below expectations. Organically, we expect OpEx growth in the second half to land in the low to mid-single digit range. EBIT before special items came in at DKK 2.068 million, a decline versus last year, with the EBIT margin contracting 1.5 percentage points. That reflects, despite a very strong gross margin, shall we say, reduced leverage across our OpEx cost base, which is likewise why we've undertaken the initiatives mentioned earlier to restore the EBIT margin and to align OpEx growth more closely, and more effectively, with the top line growth we anticipate. Cash flow was solid. Cash flow from operations came in at just under DKK 1.5 billion. The decline versus last year stems from higher tax payments and greater net financial expenses. Capital expenditure has come down, now at 3% of group revenue, since, broadly speaking, we've invested less in property, plant, and equipment.

René Schneider executive
#12

Acquisitions consumed DKK 763 million in net cash, and acquisition remains a key element of the strategy in our view, and you should expect that to continue going forward as well. During the first half year, the share buyback came to DKK 1.137 million, and 3.3 million shares were repurchased. And also we've provided an updated outlook, and we now expect 2.3 for the full year. Turning to the balance sheet, it grows 6%. That is purely a result of acquisitions, while organic growth and the exchange rate impact were roughly flat. If you notice a significant movement on some of the individual items, that stems from the fact that the communications business is now classified as held for sale and reported in that manner. Interest-bearing debt came in at just shy of DKK 14 billion, and leverage at the end of the period stands at 2.3, which falls within our guidance range. So let me go a bit further into the detail around the financial impact of the restructuring plan for EPOS, and also give an update on the discontinued business more broadly. As a reminder to everyone, there are two main elements within our discontinued operations, meaning the businesses we hold for sale.

René Schneider executive
#13

First, there's our communications business, and second, our hearing implant business. So let me point you toward the table on the right-hand side, and let's take the communications business first. The table shows that in the first half year of 2024, the communications business was loss-making. However, for the second half year of 2024, what we expect is a continued loss in Q3. Yet in light of the restructuring we are carrying out, or intend to carry out immediately, a profitable fourth quarter is what we will see. The restructuring's one-off impact is a negative impact of DKK 400 million. Of those DKK 400 million, we estimate that roughly DKK 75 million will be the cash effect alone, while the remaining DKK 325 million is non-cash. Basically, you can say it is a balance sheet revaluation of the various items tied to the communications business. So putting this together for the full year, we now expect a net operating loss of DKK -500 million, versus the previous DKK -100 million-DKK -150 million. But again, much of this, or the majority, is non-cash. Turning to hearing implants, when we evaluate the first half year, it consists of two elements.

René Schneider executive
#14

First, there's the bone-anchored operation, which remains held for sale. That business is profitable — it was profitable through the first half of the year and keeps being profitable in the second half. In contrast, we recorded a loss of DKK 87 million in the CI business. Some of that stems from operations, while the rest comes from the transaction itself, through write-downs of the remaining balance sheet items. For the second half, now that we're out of CI, the expectation is that the bone-anchored business will deliver a profit. So the revised expectation for the full year is DKK -50 million from the hearing implants across the whole year. What that adds up to for the year is a net loss of DKK 550 million. Once again, a substantial portion of that is non-cash, and what we hold on our books at year-end as a business is two operations for sale, both of which are profitable and will remain profitable as we go into 2025. With that, we'll pass it over to outlook.

Søren Nielsen executive
#15

Thank you very much for that. Looking at the slide we have up now — everything regarding the discontinued operation that you've just walked through, that's the sole modification, so we'll move past this slide and there's no further need to elaborate. Regarding the outlook, you've already heard all the key points. The one thing added to what we shared on the discontinued business is, you might say, a stance on what we anticipate for share buybacks: we now expect to repurchase shares worth roughly DKK 2.3 billion, whereas earlier we had indicated a figure above DKK 2 billion. With that said, I believe we should move straight into Q&A.

Operator operator
#16

We're going to start the Q&A portion now. If you'd like to ask something, just hit star followed by one on your touch-tone phone. Should you be on a speakerphone, lift the handset first before you press that key. And whenever your question has already been covered and you'd prefer to drop it, press star, then two. Right now we'll take a brief pause to put our roster together. Today's opening question is from Martin Parkhøi at SEB. Go ahead, please.

Martin Parkhøi analyst
#17

Good afternoon. This is Martin Parkhøi from SEB, and I have two questions — one about managed care and one about EPOS. First, regarding managed care, could you perhaps share a bit about when you anticipate that the negative effect of the managed care strategy you've selected will start showing up in the comparison figures? And on that point, Søren, you of course mentioned that you haven't been able to fully offset the managed care loss through more sales and independent. In my experience, if that were going to happen, it would probably have happened immediately. But do you still think that impact could appear later on? Then my second question is just on EPOS. You're now taking steps to restructure EPOS so it becomes more profitable and more attractive. But if, after this, you also can't find a buyer and you choose to shut it down, how much extra cost should we expect from that? Or is that perhaps already included in the restructuring you're carrying out in the second half?

Søren Nielsen executive
#18

Yes, thanks, Martin. I'll start with managed care. The annualization kicks in once we get to the second quarter, which is after the first quarter. When we say not fully compensated, the truth is it arrived more or less overnight, and there's no way you can see that effect that fast. These managed care players, they continue referring patients, and for some it's only natural that they're then in a different position to promote Oticon products or the newest technology from Oticon. For others, though, it's also a matter of training and a way of looking at their own business. So when the negative effect shows up, it's basically immediate, and there's no way to fix it right away. I certainly expect positive sentiment around the strategy for the independent to keep going, but naturally I also expect growth in managed care. We aren't doing this in order to stay out of managed care. We're doing it to position our brands better across the different channels, so that people, you might say, have a free choice, and you can see different products and different service models also somewhat justified at different pricing.

René Schneider executive
#19

And regarding your EPOS question, Martin — while this restructuring is quite substantial, covering both balance-sheet and, say, organizational aspects, it captures only the current plan, correct? So nothing tied to the scenario you're sizing is incorporated, and we definitely don't anticipate finishing there. We see it as an extremely strong plan that brings OpEx spending down to under 50% of last year's level. And the sales level needed for that company to turn a profit aligns with, or is in fact a bit below, what we've been delivering for quite a few months now.

Martin Parkhøi analyst
#20

But let me just ask a quick follow-up there, René. Among the folks you're about to speak with, do some of them already expect that they'd be interested once this restructuring is done? And I'm not clear on this — if they're genuinely keen on the asset, why wouldn't they simply handle it on their own?

René Schneider executive
#21

Martin, we've been clear that this item has stood in the way of reaching an agreement, though it doesn't carry a commitment from the other side, obviously. But our assessment is that this is what's needed to make it an asset that buyers would also be ready to sign an agreement on, yet it comes without a specific commitment. And obviously, we're on the inside, and we know how we can undertake such a restructuring. That is, of course, difficult when you're on the outside, even though you have access to all the data.

Martin Parkhøi analyst
#22

Alright, thanks a lot.

Operator operator
#23

Our following question is from Julien Ouaddour at Bank of America. You have the floor.

Julien Ouaddour analyst
#24

Hello there, and good afternoon to everybody. So, my first — apologies, I actually have two. My first one concerns product. I'm certain you've examined what your biggest rivals are doing and the launches they've made. So I was curious about your reaction to the fact that they likewise opted for, say, deep neural network technology? Let's assume they managed as well to fit a second chip into the device so real-time AI could run. So did you pursue that as well, or did it catch you off guard, and how does it mainly differ from your DNN version? My second one relates to guidance. Previously it has happened that guidance of that kind turned out slightly optimistic. On this occasion your assumptions appear cautious, particularly around managed care and with independence. So I was just wondering whether more downside could lie ahead here? And, you know, what does the bear case scenario look like that reflects the bottom end of the guidance? Thank you.

Søren Nielsen executive
#25

Yeah, thanks a lot. I think there’s only so much we can say about competition. What we’ve seen is just very high-level presentations, and naturally, all of the material was made to impress customers and leave a really good impression behind. I think the key thing is — I’ve been asked many times what the next paradigm shift in hearing aids and technology will be. And I’ve said on numerous occasions that I believe AI-driven processing is the future. You get speed, and you get an ability to recognize things that are otherwise very, very hard to detect and to react to. And our core purpose when designing a hearing aid is to improve the signal-to-noise ratio — meaning making speech clearer. We’ve worked on this across now three product releases, and we feel we’re a significant step up the curve in utilizing these technologies, whether they’re then made with one chip or two chips or so on. I think everyone knows today that a deep neural network depends on how you’ve trained it, what it has learned, how fast it is, and so on. I feel we’re very mature. We’re well positioned to compete in this space.

Søren Nielsen executive
#26

That's really the heart of hearing aids—how they're designed. And once more, I spend less on that. To me, it matters less whether one chip or two chips are used, or whether it's what people call a dedicated AI chip versus something running on a standard DSP. That isn't the real challenge or the point, in my view. What matters is whether your network has been trained so it truly understands what to search for and what action to take once it finds it. Those remain the essential elements. You can't outperform the engine you're actually affecting and, you know, the outcomes you're able to achieve. So we believe we're well positioned, and this serves as confirmation and evidence of our strategy and the way we've anticipated future technologies. I can't say whether guidance is optimistic or conservative. Our aim is always to present our best view of things, and uncertainty exists. Our industry is highly competitive and somewhat dynamic. This represents our best assessment as of now—done in July and reaffirmed at present—and it reflects a realistic ambition for the full year.

Julien Ouaddour analyst
#27

Thank you very much, Søren. Let me just add to the second question, if I may. So, I mean, could there be a possibility of, say, further erosion in market share where managed care is concerned, or would you say we have more or less hit the floor right now? And the same goes for independence — or rather, what have you actually assumed in the guidance regarding, let's say, market share momentum for H2?

Søren Nielsen executive
#28

Yeah. Market share is, sorry, a strange beast. Are we discussing units? Or revenue? Obviously, I think our figures show that premium products and solutions are selling well, particularly in channels with favorable pricing—hence a robust ASP. So in this situation, we essentially anticipated some continuation of that during the second half, and where I do think we'll hopefully pick up more is in a few of those high-volume areas where we've been losing. Thus, I'd characterize the second half as a more even split between units and ASP. As for the first portion of your follow-up—whether further share loss in managed care is possible—I'd say that would be quite hard at this point. So on that front, as we move forward, upside outweighs downside.

Julien Ouaddour analyst
#29

That's great. Thanks so much.

Operator operator
#30

Our following question is from Maja Pataki at Kepler Cheuvreux. You have the floor.

Maja Pataki analyst
#31

Good afternoon. I also have two questions for you, Søren. When it comes to managed care, we've discussed how you've lost considerable share, and you've said it's hard to lose much more, but at your Capital Markets Day you mentioned wanting to make Bernafon the managed care brand. Could we talk a little about where you stand in that process? Are they willing to listen? Are they presently so irritated that they won't even consider the product? It would really help to understand how things look on that front. And then there are, you know, a few hopes in the market, I'd say, that 2025 will be a strong year, since the reform in France is being analyzed, and that should produce fantastic market growth, so you ought to benefit. Looking at what happened in Germany, that's clearly something we've observed. Do you have any expectation for what the French market might look like in 2025? Thank you.

Søren Nielsen executive
#32

Yes. Thanks, Maja. To start with managed care, I'd say that, broadly speaking, we're having productive and positive business conversations with every player involved. Our strategies have been laid out. There's also no question that, when it comes to technology, Bernafon isn't that well known in the U.S. We've been selling it in many other parts of the world for a longer stretch of time. I think we're getting to the stage where people recognize it's also excellent technology and that it represents the newest technology from the group. Whether that's sufficient to sign contracts and get onto formulas, it's still too early to tell, but I'd say we're having good, good constructive conversations with a number of players, and we definitely see and expect Bernafon to be listed with some of those players — if not already, then very soon.

Maja Pataki analyst
#33

So,

Søren Nielsen executive
#34

And.

Maja Pataki analyst
#35

Sorry to jump in there — just a quick follow-up on that.

Søren Nielsen executive
#36

No, no.

Maja Pataki analyst
#37

Just to follow up quickly on that point. From experience, when you mention constructive conversations, once an agreement is reached and products begin selling and flowing into your numbers, what sort of timeframe does that involve? Could it be turned around in a month, or is it more of a three-month timeframe? Just so we have some sense of how a possible path forward might look.

Søren Nielsen executive
#38

Right. And of course, there's no way for us to state that with certainty, since we lack experience in it. A training effort will be required. Success and trial will be required. In other markets, I can say, we've been through comparable — you might call it — repositioning of our brands. And yes, it does take some time before you become accustomed to new things and the fitting system and so forth. But our training divisions, our salespeople, are prepared for that. It's happening in, you know, the very same outlets where we come to conduct training on Oticon. So it isn't as though this is a completely new channel. The people who purchase it are one part of the system. They never touch the device. The actual fitting takes place with customers we know well, and so I expect they will likewise pay attention to the necessary training and so forth, if they're interested in being on the contract with these — the TPAs. So I can't tell you at this moment precisely what I expect. I believe we ought to exercise some caution about being, you know, overly optimistic, but on the other hand, you know, it will, I'm certain it will come.

Søren Nielsen executive
#39

Moving on to the second part, the French market. I think it's certainly going to be positive, since we saw such an enormous in-sale and influx of primo next year, without a doubt. There's also the fact that when a hearing aid has come to you at no cost, some people wind up not using it and are never truly satisfied. As a result, you do lose a somewhat larger share. We're aware that this happens in other markets that have a free-to-client channel, so we can't simply calculate mathematically how many remain active and require a new hearing aid, but I expect a substantial share of those who received one four years ago will now be checking whether the moment has arrived for an upgrade.

Maja Pataki analyst
#40

Thanks — that's great, and I appreciate it.

Operator operator
#41

Our following question is from Niels Granholm-Leth at Carnegie. Please proceed.

Niels Granholm-Leth analyst
#42

Thanks. So regarding the repositioning of your brand, it appears you're no longer a supplier, or you've reduced your supplierships with a number of larger chains. Does that stem from the same shift in branding strategy as what's happening in managed care? And does it carry any implications for your willingness to make private label hearing aids? Thank you.

Søren Nielsen executive
#43

Sure, that one's pretty straightforward. No — the brand repositioning is strictly a U.S. managed care matter, or rather a strategic decision. Everything else, I'd call it ordinary business conversations, and I'd say our first half was a bit disappointing, and in fact, within the commitments we have, we expect sales to grow in the second half. If everyone honors the agreements we've got, there should be a nice upside for us in the second half, and nothing has changed about our ability or our willingness to do private label or anything like that. No, no changes. No changes.

Niels Granholm-Leth analyst
#44

So it's not the case that by getting stricter about pricing with some of the larger chains, you've ended up no longer being present?

Søren Nielsen executive
#45

When it comes to bigger players, pricing is always something we discuss, and every so often they choose to go a different way; every so often we, on the manufacturing side, make a decision to adjust what we charge, so that conversation keeps going. Naturally, we're not in some unusual position at the moment. What we're seeing, I believe, is simply the outcome and fallout of the talks held in 2023, along with the business moving forward, and of course we keep checking whether we feel we've landed on the correct price points and the right pricing, balancing that against earning money on that channel as well.

Niels Granholm-Leth analyst
#46

Thanks a lot. Appreciate it.

Operator operator
#47

Our next question is from Veronika Dubajova at Citi. Please go ahead.

Veronika Dubajova analyst
#48

Hi, guys. Good afternoon, and thanks for taking my questions. I have two, please. First, I'm just trying to understand how much the downgrade to organic revenue growth guidance has changed in magnitude. Even if I made a fairly sizable assumption about your managed care business and assumed it has gone entirely to zero without any offset, it's clear that something else is happening. So I was just curious if you could kind of outline, you know, the magnitude of impact when I look at the downgrade to the organic. How much is driven by managed care? How much is driven by those large accounts, and to what extent are you reflecting anything else that might not have gone fully to plan when you kind of downgraded the guidance a month ago? So if you can maybe just elaborate. I know there's been a lot of focus on managed care, but mathematically, there must be something else going on that's not just managed care. So if you could talk through that, that would be helpful. And then the second thing is just on the market dynamics. Obviously, we heard this from Amplifon. It remains a theme that the European market is subdued.

Veronika Dubajova analyst
#49

I'm just curious about your take on what's happening and how much longer we'll need to wait. What has to shift for momentum in that market to pick up and get back to the historical norm? We've been sort of, you know, scraping along the bottom for 24 months now. When will things improve, and what do you figure needs to change? Thanks a lot.

Søren Nielsen executive
#50

Let me start with revenue. Managed care and our brand strategy are the majority and the single biggest factor. But there's also — if we say that was roughly a third of things — roughly a third that happens to relate to other topics around the hearing aid business, and I'll mention an example or two afterward. And then, of course, there's also diagnostics and hearing care, China as an example. Other things in hearing aids. One example is we had higher expectation for growth in the VA channel, growth in the size of the VA channel. We had not in our plans, and we had hoped for recovery during the year. We have not seen that, that it would get up and show normal and regular market growth that we have normally seen. So that's just an example. Then we spoke to some of the bigger, you know, channels moving high volumes at lower prices, and as I just replied in the answer to Niels, we have seen some where we have been below expectation in first half and have some upsides in second half, but we have also seen others where we have not managed to regain that momentum, and therefore, yes, that's the total picture.

Søren Nielsen executive
#51

On diagnostics, I've already gone through the reasons, and once again it comes down to market factors. With China, you might frame it as market access, and near term we don't expect significant movement on either front. Over the long term, naturally, we hold to the same view on diagnostics. Turning to China, hearing care offers another instance where at the start of the year we anticipated substantial improvement as the year progressed, yet that has not materialized. So those are the examples, Veronika, and certainly beneath the surface there are a few further specifics, but these represent the larger items.

Veronika Dubajova analyst
#52

That's useful. So then, what's your view on how the market is growing in Europe, and what would it take to get it back to the historical norm?

Søren Nielsen executive
#53

France obviously plays a major role in that. We did have a surplus in one year, and then it was lower for the next two years. But when you look at France across three, four, or five years, the conclusion you reach is quite favorable. We've noticed some renewed momentum in Germany, though the baseline growth expectations there are somewhat weaker than in many other markets, largely because of demographics. And then the U.K. has been shown to rise and fall based on how efficient the National Health Service's total supplies are. You can see just how widely it can swing from one quarter to the next. So that's essentially it. Europe overall has historically been below both North America and the rest of the world, again because of demographics, but we should certainly expect a higher average — perhaps closer to 3%-4% rather than the 4%-6% we typically see.

Veronika Dubajova analyst
#54

Appreciate it. Thank you very much.

Operator operator
#55

Our next question is from Martin Brenøe at Nordea. Go right ahead.

Martin Brenøe analyst
#56

Hello, and thanks so much for taking my questions. Most of them have already been addressed, so I'll keep it to two housekeeping items, if that's alright. The first concerns the gross margin you posted in H1, which is really quite impressive. Could you perhaps shed a bit more light on how sustainable that level is? And also, given what you've said about larger accounts with no ASP, where you're seeing some momentum once again, could you expand a little on how we ought to think about gross margin for H2 and perhaps somewhat further out as well, specifically how structural this margin is? On the OpEx side, I understand the organic piece of the equation. How much should we anticipate in OpEx growth during H2 stemming from, say, the acquisitions you've completed over the past 12 months or thereabouts? Thank you.

René Schneider executive
#57

Okay, hi Martin. I'll try to tackle these questions. On gross margin—yes, you could call it unusually high, and normally when we give soft guidance on this, we guide to 76%-77% gross margin. So 76.8% is definitely at the high end of that, and it's driven by the factors we've already talked about. And you could say that going into the second half, if, as we expect, we see, let's say, a more normal product mix, given customer and geographical mix as well, then you're likely to see a slight setback on gross margin. Still higher than last year, I'd say. On the OpEx side, yeah, we went through the organic part, but expect the acquisition contribution to be similar to the first half year.

Martin Brenøe analyst
#58

And maybe, just so I understand it properly, could you walk me through a bit of what’s in the toolbox — what levers you can pull to reduce costs in your core business?

René Schneider executive
#59

So you're talking about the general situation there. Yeah, that's right — but that's the result of it.

Martin Brenøe analyst
#60

We’ll go ahead and start the program.

René Schneider executive
#61

Okay. So because we ended up below both our own expectations and our guidance, we've put in place — you could call them — general policies across the whole company on expenses, whether that's hiring or replacements, and overall a strong emphasis on prioritizing activities. Making sure, again, in a very generic sense, that we keep a short-term focus on activities that generate sales, and perhaps delaying somewhat more those things with a longer-term outlook. You could say internal events, that kind of thing as well. So it's quite broad-based across the P&L, and it essentially applies globally too, and in every business area. But naturally, sales is the focus where we don't, let's say, cut short on things.

Martin Brenøe analyst
#62

Understood — thanks a lot, René. And thanks for taking my questions.

Operator operator
#63

Christian Ryom from Danske Bank has the next question. Go ahead, please.

Christian Ryom analyst
#64

Yes, good afternoon, and thanks for taking my questions. I have two as well. The first one is for the diagnostics business, and specifically what the prospects look like for that business in the European market. So as I read your report, I understand that European markets were a drag on growth. And my question is basically whether that's a temporary dynamic, in your view, or something that could extend for a few more quarters, or for coming quarters. And then my second question is on whether, or to what extent, the wholesale brand decision that you've taken vis-à-vis managed care, in the U.S., is also impacting your retail hearing care business? And if so, how meaningful that is? Thank you.

René Schneider executive
#65

Hi Christian. Regarding diagnostics in Europe, a major factor we’re highlighting is a notable decline in sales to the NHS, where similar dynamics are at play—both in staffing and in capital equipment spending. We don’t have any specific insights into when their way of operating will return to normal. Of course, we expect some improvement in the second half of the year. Right now, though, on a run-rate basis, they are well below last year. That is the key driver for Europe.

Søren Nielsen executive
#66

Regarding hearing care in the U.S. and the brand strategy with managed care, prior to the decisions being made and implemented on the brand strategy on wholesale, we were already working to reduce how much managed care was in our HearingLife business in the U.S., and we can only say that the decisions that were made have given further support to this process. So we now have, I think, a close — I would dare to say, all-time low share of it, and we have succeeded in the transition to more cash pay.

Martin Brenøe analyst
#67

I appreciate it.

Operator operator
#68

David Adlington from JPMorgan has the next question. Go ahead, please.

David Adlington analyst
#69

Hey, guys, thanks for the questions. So, again, apologies once more — on managed care, it may not come across that way, but I just wanted to double-check whether you're thinking about any shift in strategy there, given that it hasn't gone quite as planned. And then second, just regarding China, I was wondering what your thoughts were there about seeing a recovery in the market. Should we expect that in the second half of this year, or perhaps more looking into next year? Thank you.

Søren Nielsen executive
#70

Yes, thank you, David. You've got the full picture correct. Nothing has changed. I'd say the takeaway is that the immediate adverse response — or the short-term effects — were larger, and explaining the strategy and actually witnessing its benefits also requires a longer period. We certainly believe as well that there are advantages for the managed care participants in gaining access to the Bernafon brand. So it simply is taking more time than we expected, and the near-term effects are larger. Regarding the Chinese market's recovery, the main problem is that we lack statistics, so fundamentally it starts as a substantial estimate, plus somewhat what is happening at some of our strong customers and what is happening in our own stores, and then extrapolating that to an assumed market size or, you know, count of outlets in the market. So it is hard, and we have, you know, we are not building our plans around a major recovery, this year. We, of course, still expect that China will eventually come back to growth. There are many untreated hearing losses, and once the financials are there, I think we will see both a rise in volume and, once more, an increasing ASP in the market.

Søren Nielsen executive
#71

Both of the things that are under pressure right now are involved. People who buy are purchasing less or spending less, and some of those who were unsure about whether to buy are holding off. In China, a lot of hearing aids get paid for by children, and if unemployment rises, we do see — not automatically, but we do see fairly soon afterward — a consequence, and that is the exact reverse of what happens elsewhere in the world, where the baby boomer generation is, in fact, a well-off generation that pays its own bills.

Operator operator
#72

Our following question is from Robert Davies at Morgan Stanley. The line is yours.

Robert Davies analyst
#73

I appreciate you taking my questions. First, regarding the Bernafon versus Oticon offering—I was wondering, from the standpoint of reaching the target audience, whether this is a brand problem or a technology gap. Is it the Oticon product that's creating the concern? I'm curious about the main areas where customers have pushed back. Second, on your comments about compensating for managed care volume through extra growth in the independent channels—what do you see as the primary reason you've had difficulty achieving that volume growth in the independent channels? Thank you.

Søren Nielsen executive
#74

Yes, thanks a lot for that question. On your first question, I'd say it comes down to awareness, reputation, and track record. Oticon holds an extremely strong brand position in the U.S., with a long heritage, and it's well recognized in the market, whereas Bernafon is comparatively unknown — so it's not merely a matter of training, of explaining and demonstrating that this technology is just as strong as Oticon's and will produce strong results for patients and users. That, I definitely believe, we can resolve in time. Keep in mind, we have only just relaunched Bernafon with a refreshed brand positioning, and we've also altered the strategy. If you look back, say, 5 or 10 years, those other brands tended to arrive later with new technology. Nowadays, every one of our brands carries the latest technology, more or less simultaneously, so we also need to ensure that any channel, when picking a brand, feels at ease and knows they get access to the newest technology. That holds true for Bernafon, and it's part of making sure that's clearly understood. Then, returning to the compensation point, as I attempted to explain earlier, we simply lost it so quickly that there was no opportunity to compensate.

Søren Nielsen executive
#75

Honestly, I do believe there's been a response — and, yeah, a kind of motivation coming from customers. That said, habits stay habits, and the real question is: how do I actually make this work for me? What do I gain from it, and how do I justify buying direct? Some people find it completely natural and simple. With others, you've got to assist them in getting better at articulating, you know, the options that the user actually has.

Robert Davies analyst
#76

Yeah—mind if I quickly add one follow-up about the unusually wide growth gap between the U.S. commercial channel and VA? It's clearly quite stark, right? In the commercial channel, I believe you posted 13% and 6%, while VA came in at -1% and 1%. As we look ahead to the second half of this year, do you see any chance for that gap to narrow?

Søren Nielsen executive
#77

No — and that ties into how we've been adjusting our expectations as well. As far as we can tell, the budget restrictions affecting VA overall haven't shifted. This isn't something specific to hearing. It's VA across the board, and there are considerable limits on how much they can rehire staff. Why is that? Essentially you've got a staffing shortage, and because of it, a capacity shortfall. The one thing that would make a difference is getting those vacant roles filled, which would bring more capacity into the system. And then, on the other side, I'd imagine you'd see something like a boom. There's definitely a pent-up demand element within VA. Some of it may be shifting over into the private market. We see that in Denmark too, and in other government settings, you know, where there's a government channel that's free to the client — once the waiting list grows too long, some people just switch channels. So that could also be part of the reason we've seen the growth we have on the commercial side: some veterans may be opting to go private.

Robert Davies analyst
#78

Got it. Thanks.

Operator operator
#79

Our following question is from Shubhangi Gupta at HSBC. Please proceed.

Peter Pudselykke executive
#80

Okay, I believe the line wasn’t open at that point, but let us know if a follow-up question comes up, and we’ll be glad to assist afterward. So, just for everyone, thank you very much for being on the call today. Should you have any additional questions, you know how to get in touch with us, and we hope to see most of you on the road during the next couple of weeks. Enjoy the rest of your day. Thank you very much.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Demant A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.